ONCT-808 by Oncternal Therapeutics for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ONCT-808 overview

ONCT-808 is under development for the treatment of relapsed/refractory B-cell malignancies like B-cell non-Hodgkin lymphoma, mantle cell lymphoma, diffuse large b-cell lymphoma, primary mediastinal LBCL, follicular lymphoma, Richter’s syndrome, hematological tumors, metastatic prostate cancer and solid tumors. It is administered through intravenous route. The therapeutic candidate consists of lentiviral vector and autologous T-cells genetically engineered to express chimeric antigen receptor (CAR) targeting cells expressing ROR1.

It was under development for chronic lymphocytic leukemia. 

Oncternal Therapeutics overview

Oncternal Therapeutics (Oncternal), formerly GTx, is a biopharmaceutical company that discovers, develops, and commercializes novel targeted hormonal therapies. It develops small molecules that target hormone pathways for the treatment of various cancers, including breast and prostate cancer and other serious medical conditions. The company’s has pipeline program includes cirmtuzumab, a humanized monoclonal antibody for the treatment of chronic lymphocytic leukemia, metastatic breast cancer and and mantle cell lymphoma; TK216 for treatment of Ewing sarcoma, prostate cancer and acute myeloid lukemia and a ROR1-targeted CAR-T therapy candidate for treatment hematologic and solid tumors. It conducts preclinical development activities in the US and Europe. Oncternal is headquartered in San Diego, California, the US.

For a complete picture of ONCT-808’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.